Gemcitabine and docetaxel combination for advanced soft tissue sarcoma: A nationwide retrospective study

Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong Churl Suh, Yeul Hong Kim

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.

Original languageEnglish
Pages (from-to)175-182
Number of pages8
JournalCancer Research and Treatment
Issue number1
Publication statusPublished - 2018 Jan 1

Bibliographical note

Publisher Copyright:
© 2018 by the Korean Cancer Association.


  • Advanced soft tissue sarcoma
  • Docetaxel
  • Gemcitabine
  • Off-label use
  • Retrospective study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Gemcitabine and docetaxel combination for advanced soft tissue sarcoma: A nationwide retrospective study'. Together they form a unique fingerprint.

Cite this